Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23479904 | 0.90 | HTT (0.47) | KDM4EHTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL23480005 | 0.88 | HTT (0.44) | POLQKDM4EHTTKMT2AMEN1 | |
| SCHEMBL31096524 | 0.83 | KDM4E (0.52) | KDM4EHTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL23202468 | 0.83 | KDM4E (0.52) | KDM4EHTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL24039062 | 0.80 | POLQ (0.51) | POLQKDM4EHTTKMT2AMEN1 | |
| SCHEMBL31096548 | 0.78 | KDM4E (0.47) | KDM4EHTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL23202504 | 0.78 | KDM4E (0.47) | KDM4EHTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL23495314 | 0.78 | MAPT (0.60) | KDM4EHTTALDH1A1LMNA | |
| SCHEMBL23480012 | 0.78 | KDM4E (0.48) | KDM4EHTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL23202442 | 0.78 | MET (0.42) | KDM4EHTTKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702403-B2 | EAAT2 activators and methods of using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702403-B2 | EAAT2 activators and methods of using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230138663-A1 | EAAT2 ACTIVATORS AND METHODS OF USING THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230138663-A1 | EAAT2 ACTIVATORS AND METHODS OF USING THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20210171497-A1 | EAAT2 ACTIVATORS AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702403-B2 | EAAT2 activators and methods of using thereof | SLC1A2, SLC1A1, SLC18A2 | POLQ 3775/4885KDM4E 3928/4885HTT 197/4885 |
| US-20230138663-A1 | EAAT2 ACTIVATORS AND METHODS OF USING THEREOF | SLC1A2, SLC1A1, SLC18A2 | POLQ 3775/4885KDM4E 3928/4885HTT 197/4885 |
| US-20210171497-A1 | EAAT2 ACTIVATORS AND METHODS OF USING THEREOF | SLC1A2, SLC1A1, SLC18A2 | POLQ 3775/4885KDM4E 3928/4885HTT 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.